Table 1 Characterization of the patient cohort
| Â | TOTAL | NMDAR-AE | LGI1-AE | CASPR2-AE | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|  | RTX (n = 18) | Ctrl (n = 41) | pvalue | RTX (n = 14) | Ctrl (n = 27) | pvalue | RTX (n = 3) | Ctrl (n = 9) | pvalue | RTX (n = 1) | Ctrl (n = 5) | pvalue |
Gender; Female/Male | 8/10 | 18/23 | .595 | 7/7 | 11/16 | .406 | 1/2 | 5/4 | .100 | 0/1 | 2/3 | / |
Age at onset, y; mean (95% Cl) | Â 41.88(33-50) | Â 37.61(32-42) | Â .356 | Â 35.28(27-42) | Â 34.22(28-40) | Â .823 | Â 63.33(48-78) | Â 52.88(43-62) | Â .190 | Â 70(/) | Â 28.40(19-37) | Â / |
From onset to diagnosis, d; median (IQR) | Â 20(78) | Â 24(52) | Â .863 | Â 14.5(23.75) | Â 16(51) | Â .185 | Â 35(/) | Â 60(63) | Â .864 | Â 190(/) | Â 31(41) | Â / |
Follow-up duration d; mean (95% Cl) | Â 1058(768-1349) | 1362(1136-1587) | Â .120 | Â 1084(802-1376) | 1488(1215-1556) | Â .059 | Â 1086(/) | Â 1640(1278) | Â .926 | Â 244(/) | Â 561(640) | Â / |
Symptoms; n(%) | ||||||||||||
Seizures | 66.7% | 61.0% | .455 | 71.4% | 66.7% | .100 | 66.7% | 55.6% | .100 | 0.00% | 40% | / |
Cognitive impairment | 94.4% | 85.4% | .422 | 92.9% | 85.2% | .645 | 100% | 100% | / | 100% | 60% | / |
Psychiatric symptoms | 83.3% | 87.8% | .690 | 78.6% | 88.9% | .393 | 100% | 88.9% | .100 | 100% | 80% | / |
Decreased consciousness | Â 44.4% | Â 29.3% | Â .201 | Â 57.1% | Â 33.3% | Â .189 | Â 0.0% | Â 11.1% | Â .100 | Â 0.0% | Â 40% | Â / |
Autonomic dysfunction | 27.8% | 22.0% | .742 | 28.6% | 25.9% | .100 | 33.3% | 0.0% | .250 | 0.0% | 40% | / |
Movement disorder | 44.4% | 26.8% | .151 | 50% | 22.2% | .089 | 33.3% | 33.3% | .100 | 0.0% | 40% | / |
Fever | 44.4% | 39.0% | .457 | 57.1% | 51.9% | .504 | 0.0% | 11.1% | .100 | 0.0% | 20% | / |
CSF/MRI/EEG profiles | ||||||||||||
CSF cc; median, (IQR) | 7(67) | 8(23) | .613 | 8.5(90.5) | 12(26) | .264 | 4(/) | 2(4) | 0.282 | 2(/) | 1(62) | Â |
CSF protein; mean, (95% Cl) | Â 404.45(318-490) | Â 353.82(288-419) | Â .370 | Â 372.05(274-469) | Â 405.57(313-497) | Â .637 | Â 470.28(93-847) | Â 247.21(179-314) | Â .009 | Â 660.7(/) | Â 266.32(144-387) | Â / |
CSF pressure; mean, (95% Cl) | Â 174.72(146-203) | Â 161.46(140-182) | Â .463 | Â 182.85(147-218) | Â 170.18(140-199) | Â .587 | Â 145.00(46-243) | Â 131.66(100-162) | Â .632 | Â 150(/) | Â 168.00(121-214) | Â / |
MRI abnormalities; n (%) | 50.0% | 56.1% | .440 | 64.3% | 51.9% | .336 | 0.0% | 77.8% | .045 | 0.0% | 40% | / |
EEG abnormalities; n (%) | Â 61.1% | Â 43.9% | Â .175 | Â 71.4% | Â 48.1% | Â .137 | Â 33.3% | Â 33.3% | Â .100 | Â 0.0% | Â 40% | Â / |
CSF/Serum Ab profiles | ||||||||||||
CSF Ab positive | 94.4% | 80.5% | .252 | 100% | 88.9% | .539 | 100% | 77.8% | .100 | 0.0% | 40% | / |
Serum Ab positive | 38.9% | 61.0% | .100 | 28.6% | 48.1% | .321 | 66.7% | 77.8% | .100 | 100% | 100% | / |
Both Ab positive | 33.3% | 41.5% | .386 | 28.6% | 37.0% | .734 | 66.7% | 55.6% | .100 | 0.0% | 40% | / |
Prior 1st-line immunotherapy; n (%) | Â 100% | Â 100% | Â / | Â 100% | Â 100% | Â / | Â 100% | Â 100% | Â / | Â 100% | Â 100% | Â / |
1st-line therapy, n (%) | / | |||||||||||
MPPT | 72.2% | 97.6% | .008 | 85.7% | 93.3% | .265 | 33.3% | 100% | .045 | 0 | 100% | / |
IVIG | 94.4% | 46.3% | <.0001 | 92.9% | 55.6% | .031 | 100% | 33.3% | .182 | 100% | 20% | / |
Both | 66.7% | 43.9% | 0.092 | 78.6% | 51.9% | .176 | 33.3% | 33.3% | .100 | 0 | 20% | / |
RTX therapy | ||||||||||||
Time from RTX therapy, d; median (IQR) | Â 74.5(410) | Â / | Â / | Â 128.5(405) | Â / | Â / | Â 6(/) | Â / | Â / | Â 5(/) | Â / | Â / |
No. of RTX infusions, n; median (IQR) | Â 5(4) | Â / | Â / | Â 5(3) | Â / | Â / | Â 3(/) | Â / | Â / | Â 3(/) | Â / | Â / |
Cumulative RTX dose, g; median (IQR) | Â 500(400) | Â / | Â / | Â 500(300) | Â / | Â / | Â 300(/) | Â / | Â / | Â 300(/) | Â / | Â / |
1st to last infusion, d; median (IQR) | Â 389(864) | Â / | Â / | Â 457.5(863) | Â / | Â / | Â 15(/) | Â / | Â / | Â 214(/) | Â / | Â / |
Averaged doseof Prednisone, mg/day; median (IQR) | Â 4.375(7.67) | Â 27.13(21.67) | Â <.0001 | Â 5.563(4.011) | Â 28.89(21.67) | Â <.0001 | Â 0 | Â 10.83(19.52) | Â .009 | Â 0 | Â 25.71(20.057) | Â / |
Relapses; n (%) | ||||||||||||
After 1st-line therapy | 33.3% | 12.2% | .074 | 42.9% | 18.5% | 0.140 | 33.3% | 0.0% | .250 | 0 | 0 | / |
After RTX therapy | 0 | / | / | 0 | / | / | 0 | / | / | 0 | / | / |